The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …

Head and neck squamous cell carcinomas (HNSCCs) are an aggressive, genetically
complex and difficult to treat group of cancers. In lieu of truly effective targeted therapies …

Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective
in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast …

Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based …

Background: Cancer is one of the leading causes of death worldwide. Over the years, a
number of conventional cytotoxic approaches for neoplastic diseases has been developed …

Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next
generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the …

Chimeric antigen receptor T (CAR-T) cell therapy is an emerging and effective cancer
immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved …

The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …

Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Summary On July 1, 2014, the United States Food and Drug Administration granted
'breakthrough therapy'designation to CTL 019, the anti‐CD 19 chimeric antigen receptor T …